Companies Dominating the Propionic Acidemia Landscape
- Cardiva Grifols SA
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CSL Behring
- Octapharma AG
- Sanquin
- Kedrion SpA
- Shire
- China Biologic Products Holdings Inc.
- Teva Pharmaceuticals
- Wellona Pharma
- Merck
- AdvaCare Pharma
Browse Key Market Insights with Data Illustration:
In the News
- In May 2023, Moderna, Inc, a biotechnology company pioneering courier RNA (mRNA) therapeutics and immunizations, expressed that an unique announcing on between times information from the Stage I/II trial of mRNA-3927, an investigational mRNA treatment for propionic acidemia has been acknowledged for introduction at the 2023 American Society of Quality + Cell Treatment Yearly Assembly being held May 16-20, 2023 in Los Angeles, CA.
- In Eminent 2022, BridgeBio Pharma expressed the Dosing of the Primary Understanding within the Stage I Trial of BBP-671, a Potential best-in-class treatment for propionic acidemia and methylmalonic acidemia (MMA)BBP-671 is an investigational verbal treatment expecting to extend CoA levels by allosterically balancing pantothenate kinases, key proteins within the CoA biosynthesis pathway.
